Arkadios Wealth Advisors bought a new position in Exelixis, Inc. (NASDAQ: EXEL) during the undefined

Amundi cut its position in Exelixis, Inc. (NASDAQ: EXEL) by 77.9% during the first quarter, accordin

Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET

Exelixis NASDAQ: EXEL reported second-quarter 2026 revenue of approximately $629 million, including

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performe

Exelixis, Inc. (EXEL) Q2 2026 Earnings Call Transcript

Exelixis (EXEL) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Est

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

Krystal Biotech is posting strong sales thanks to a breakthrough in an underserved therapeutic area.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raise

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quar

Bank of New York Mellon Corp lowered its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 2.8%

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings bea

Allspring Global Investments Holdings LLC grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 23.4

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combin

Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the

Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and r

These three biotechs are posting strong revenue growth. Brand-new launches and label expansions shou

Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market l

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

Top Wall Street analysts changed their outlook on top names. See all rating changes, including upgra

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1

Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is estimated to report earnings for it

  On Tuesday, 838 companies hit new 52-week lows.

  During Monday's trading, 528 companies set new 52-week lows.

Stocks Which Set New 52-Week Low Yesterday, October 29th

Stocks Which Set New 52-Week Low Yesterday, October 23rd